MetaCap

Abeona Therapeutics (ABEO) vs Entrada Therapeutics (TRDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Abeona Therapeutics (ABEO) has outperformed Entrada Therapeutics (TRDA) over the past year, losing 46.0% versus a loss of 57.0%. Over five years, TRDA leads with a -85.0% price change compared with -86.7% for ABEO. Entrada Therapeutics is the larger company by market cap ($170.3 million vs $165.3 million), about 1.0 times the size.

Abeona Therapeutics converts more of its revenue into profit, with a net margin of 1223.1% versus -565.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABEO-45.98%TRDA-56.97%
+73%+5%-63%
Nov 21, 20251 yearNov 20, 2026
ABEO-86.92%TRDA-86.73%
+4%-44%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABEO versus TRDA key metrics
MetricABEOTRDA
Share price$2.42$4.35
Market cap$165.31M$170.30M
1-day change-1.22%-6.25%
YTD return-54.08%-57.68%
1-year return-45.98%-56.97%
5-year return-86.74%-84.95%
EPS (TTM)$-1.16$-3.84
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.82M$25.42M
Revenue growth (YoY)—-87.94%
Net income (latest FY)$71.18M$-143.75M
Gross margin73.68%—
Operating margin-1536.91%-621.13%
Net margin1223.08%-565.48%
52-week high$7.65$16.45
52-week low$2.09$4.11
Distance from 52-week high-68.37%-73.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+542.98%+308.05%
Average volume1.66M401.15K
Shares outstanding68.31M39.15M
Employees226152
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABEO has outperformed TRDA by 11.0 percentage points over the past year.
  • Abeona Therapeutics is more profitable, keeping 1223.1 cents of every revenue dollar as net income versus -565.5 cents for Entrada Therapeutics.

About Abeona Therapeutics

ABEO stock →

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.

Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees

About Entrada Therapeutics

TRDA stock →

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees

ABEO vs TRDA FAQ

Which is bigger, Abeona Therapeutics or Entrada Therapeutics?

Entrada Therapeutics (TRDA) is larger, with a market capitalization of $170.30M compared with $165.31M for Abeona Therapeutics (ABEO).

Which stock has performed better over the past year, ABEO or TRDA?

ABEO returned -45.98% over the past 12 months, compared with -56.97% for TRDA (price return, excluding dividends). Past performance does not predict future results.

Are Abeona Therapeutics and Entrada Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons